Does XOMA Royalty (XOMA) Have the Potential to Rally 85.34% as Wall Street Analysts Expect? — Positive
XOMA Zacks Investment Research — September 19, 2025The average of price targets set by Wall Street analysts indicates a potential upside of 85.3% in XOMA Royalty (XOMA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Should You Buy Shattuck Labs, Inc. (STTK) After Golden Cross? — Positive
STTK Zacks Investment Research — September 19, 2025Shattuck Labs, Inc. (STTK) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, STTK's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
Wall Street Analysts Think Fiverr (FVRR) Could Surge 26.93%: Read This Before Placing a Bet — Positive
FVRR Zacks Investment Research — September 19, 2025The mean of analysts' price targets for Fiverr (FVRR) points to a 26.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
SABLE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Sable Offshore Corporation and Encourages Investors to Contact the Firm — Neutral
SOC GlobeNewsWire — September 19, 2025Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Sable (SOC) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Sable between May 19, 2025 and June 3, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
ProKidney: Slow-Burning 'Buy' Opportunity Based On 2027 Approval Of Kidney Disease Therapy — Positive
PROK Seeking Alpha — September 19, 2025I rate ProKidney a buy due to promising Phase 2 data for rilparencel in advanced CKD, strong FDA alignment, and sufficient cash runway. PROK's Phase 3 PROACT 1 study uses eGFR slope as a surrogate endpoint, with topline data expected in Q2 2027 and potential for accelerated approval. The company halted its second Phase 3 trial, saving over $150m, and expects positive REGEN-007 results to be presented at ASN Kidney Week in November.
Will Medifast's Strategic Endeavors Deliver Growth in 2025? — Positive
MED Zacks Investment Research — September 19, 2025MED boosts growth efforts with new products, digital tools and an expanded OPTAVIA coaching network.
Bet on Low-Beta Stocks STNG, BZ & TME as Market Uncertainty Remains — Neutral
BZ STNG TME Zacks Investment Research — September 19, 2025Scorpio Tankers, Kanzhun and Tencent Music emerge as low-beta picks to help investors navigate ongoing market volatility.
ExxonMobil's Permian Push: Leveraging Technology for Production Growth — Positive
XOM Zacks Investment Research — September 19, 2025XOM boosts Permian potential with new tech, lifting recoverable resources and targeting 2.3M boe output by 2030.
PTC Unveils Arena AI Assistant & Supply Chain Intelligence Enhancements — Positive
PTC Zacks Investment Research — September 19, 2025PTC expands its Arena portfolio with an AI-powered assistant, new supply chain tools and CAD-PLM integration to boost collaboration and efficiency.
Here's Why Curtiss-Wright (CW) is a Strong Momentum Stock — Positive
CW Zacks Investment Research — September 19, 2025Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Dropbox (DBX) is a Strong Momentum Stock — Positive
DBX Zacks Investment Research — September 19, 2025Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Aptiv PLC (APTV) is a Strong Momentum Stock — Positive
APTV Zacks Investment Research — September 19, 2025Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Qorvo (QRVO) is a Top Momentum Stock for the Long-Term — Positive
QRVO Zacks Investment Research — September 19, 2025The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Ralph Lauren (RL) is a Strong Momentum Stock — Positive
RL Zacks Investment Research — September 19, 2025The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why TransMedics (TMDX) is a Top Momentum Stock for the Long-Term — Positive
TMDX Zacks Investment Research — September 19, 2025Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Vornado (VNO) is a Strong Momentum Stock — Positive
VNO Zacks Investment Research — September 19, 2025Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Paypal (PYPL) is a Strong Momentum Stock — Positive
PYPL Zacks Investment Research — September 19, 2025Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
FedEx Stock Higher as Earnings Beat Triggers Bull Notes — Positive
FDX Schaeffers Research — September 19, 2025FedEx Corp (NYSE:FDX) stock is up 2.3% to trade at $232.06 at last glance, after the transportation company announced better-than-expected earnings and revenue for the fiscal first quarter and hiked its full-year outlook.
Lennar: Strategic Pricing And Robust Liquidity Amid Rate Cuts Provide Some Insulation — Positive
LEN Seeking Alpha — September 19, 2025Lennar Corporation enjoys stable housing demand with its strategic pricing without sacrificing its profits. Its robust balance sheet ensures the sustainability of its large operating capacity and dividend payouts. Its valuation shows a limited upside, but it has already priced in market risks, making it reasonable at this level.
Is the Options Market Predicting a Spike in Adherex Technologies Stock? — Neutral
FENC Zacks Investment Research — September 19, 2025Investors need to pay close attention to Adherex Technologies stock based on the movements in the options market lately.